Pharmaceutical

Orano Med unveils radiopharma manufacturing plant in Indianapolis 

The facility is expected to allow Orano Med to produce 5,000 doses of lead-212 based radioligand therapies by 2025.

Jun 8, 2024 - 04:00
Orano Med unveils radiopharma manufacturing plant in Indianapolis 
The facility is expected to allow Orano Med to produce 5,000 doses of lead-212 based radioligand therapies by 2025.
Read the original article

Tags:

Previous Article

FDA admonishes Jiangsu Hengrui’s manufacturing site following inspection

Next Article

FDA AdCom to question efficacy and safety concerns with Eli Lilly’s Alzheimer’s ...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Pharmalittle: Abortion pill ruling could threaten FDA approval authority; Lilly CEO warns EU pharma legislation will hurt innovation

STAT+: Pharmalittle: Abortion pill ruling could threate...

Apr 11, 2023

STAT+: Pharmalittle: Novartis R&D hub’s name change reflects strategy shift; Lilly’s Mounjaro backed by U.K. watchdog

STAT+: Pharmalittle: Novartis R&D hub’s name change ref...

Sep 8, 2023

STAT+: Dewpoint Therapeutics cuts 15% of staff, acknowledges Merck, Pfizer broke off partnerships over buzzy science

STAT+: Dewpoint Therapeutics cuts 15% of staff, acknowl...

Jan 16, 2024